[{"id":"cb11626b-0801-40b0-ae65-d3f235f68f1d","acronym":"Iintune-1","url":"https://clinicaltrials.gov/study/NCT04420884","created_at":"2021-01-18T21:18:09.463Z","updated_at":"2025-02-25T15:18:40.036Z","phase":"Phase 1/2","brief_title":"A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04420884 - Iintune-1","lead_sponsor":"Takeda","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • 5-fluorouracil • dazostinag (TAK-676)"],"overall_status":"Recruiting","enrollment":" Enrollment 374","initiation":"Initiation: 07/22/2020","start_date":" 07/22/2020","primary_txt":" Primary completion: 01/15/2026","primary_completion_date":" 01/15/2026","study_txt":" Completion: 01/15/2026","study_completion_date":" 01/15/2026","last_update_posted":"2025-02-12"},{"id":"39769fed-659c-4bfe-8a22-cc44cf784049","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541108","created_at":"2021-01-18T21:43:38.590Z","updated_at":"2024-07-02T16:35:08.887Z","phase":"Phase 1","brief_title":"Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies","source_id_and_acronym":"NCT04541108","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-04-18"},{"id":"64bcff1a-9d20-4e04-9f94-a4766a342655","acronym":"","url":"https://clinicaltrials.gov/study/NCT06062602","created_at":"2023-10-02T20:12:31.941Z","updated_at":"2025-02-25T14:52:38.229Z","phase":"Phase 1","brief_title":"PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC","source_id_and_acronym":"NCT06062602","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • TNFA • CASP3 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • TNFA • CASP3 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • 5-fluorouracil • dazostinag (TAK-676)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 11/15/2022","primary_completion_date":" 11/15/2022","study_txt":" Completion: 11/15/2022","study_completion_date":" 11/15/2022","last_update_posted":"2023-10-06"}]